Journal of Cataract & Refractive Surgery · 2018 · 61 citations · 31 references
MedicineOphthalmologySurgeryOphthalmic SurgeryRefractive SurgeryVisual RehabilitationCorneal DiseaseCorneal ImagingCorneal OpticsCorneal TopographyPhotorefractive KeratectomyPostoperative Refractive OutcomesFollow-up DurationKeratoconus SurgeryPostoperative Visual AcuityPostoperative Visual LossTransepithelial Photorefractive KeratectomyVisual Acuity RehabilitationVisual Function LossVisual Rehabilitation After Keratoplasty
PURPOSE: To present 24-month results from the transepithelial photorefractive keratectomy (PRK)-corneal crosslinking (CXL) trial using simultaneous accelerated CXL and a new tissue-saving ocular wavefront-guided transepithelial PRK algorithm aiming to reverse visual loss in early-stage keratoconus without compromise to stabilization of disease progression. SETTING: Moorfields Eye Hospital, London, United Kingdom. DESIGN: Prospective case series. METHOD: Patients with progressive grades I to III keratoconus and logarithm of the minimum angle of resolution (logMAR) corrected distance vision acuity (CDVA) worse than 0.00 (20/20) were included. Consecutive matched historical controls treated only with accelerated CXL were the control group. The main outcome measure was change in logMAR CDVA. RESULTS: The study group comprised 47 eyes of 47 patients (mean age 24.6 years ± 3.8 [SD]). The CDVA improved from 0.28 ± 0.21 logMAR (20/60) preoperatively to 0.15 ± 0.14 logMAR (20/30) 24 months after transepithelial PRK-CXL (P < .001). Twelve eyes gained and 1 eye lost 2 lines or more of CDVA. The mean stromal ablation depth at the cone apex was 35 ± 15 μm. Significant reductions in the maximum keratometry (K) reading and coma were evident in topographic comparison maps. The controls (n = 47) had no significant changes in CDVA, higher-order aberrations, or K values. The mean K values in both groups were stable from 6 months after treatment. CONCLUSION: Ocular wavefront-guided transepithelial PRK-CXL resulted in significant gains in CDVA without compromising CXL efficacy over a 24-month follow-up.
31
Global Consensus on Keratoconus and Ectatic Diseases
José Álvaro Pereira Gomes, Donald Tan, Christopher J. Rapuano et al. · Cornea · 2015 · 1.1K citations
Medicine, Ophthalmology, Surgery +17
A Randomized, Controlled Trial of Corneal Collagen Cross-Linking in Progressive Keratoconus
Christine Wittig-Silva, Elsie Chan, Amirul Islam et al. · Ophthalmology · 2014 · 707 citations · Full text
Medicine, Ophthalmology, Surgery +13